Stock comparison
AnaptysBio
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANAB
AnaptysBio
Market cap
$2.57B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANAB | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 29F | 65C | GMAB |
| Benjamin Graham | 66D | 64C | ANAB |
| Philip Fisher | 43D | 48D | GMAB |
| Peter Lynch | 77B | 25F | ANAB |
| Joel Greenblatt | 54C | 76B | GMAB |
| Charlie Munger | 35D | 68C | GMAB |
| Terry Smith | 30F | 71C | GMAB |
Side-by-side metrics
| Metric | ANAB | GMAB |
|---|---|---|
| Market cap | $2.57B | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | 55.0x | 12.0x |
| ROIC (TTM) | 14.06% | 43.78% |
| Gross margin | 116.42% | 93.88% |
| Net margin | -11.53% | 18.23% |
| Revenue CAGR 5y | 38.82% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 21.8x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANAB leads on
- Revenue CAGR 5y38.82%vs -18.45%+148%
- P/E (TTM)-vs 6.2x+110%
- Gross margin116.42%vs 93.88%+19%
GMAB leads on
- Net margin18.23%vs -11.53%+163%
- Debt / Equity0.1xvs 21.8x+100%
- Market cap$16.5Bvs $2.57B+84%
- EV/EBIT12.0xvs 55.0x+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.